Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.
Gainers: •$ロケット・ファーマシューティカルズ(RCKT.US)$+10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy) •$カナダ・グース・ホールディングス(GOOS.US)$+9.4% (the company reported an unexpected profit as well as better-than-expected revenue) •$シガテクノロジーズ(SIGA.US)$+6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
エナンタ・ファーマシューティカルズに関するコメント
コラムTop upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more
• $A.O.スミス(AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $ダン・アンド・ブラッドストリート・ホールディングス(DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
•$エナンタ・ファーマシューティカルズ(ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $コーニング(GLW.US)$ : CFRA Upgrades to Strong Buy ...
コラムToday's pre-market stock movers: BBIO, LZB, ORA, DOW and more
• $レイジーボーイ(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $エナンタ・ファーマシューティカルズ(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $ファイザー(PFE.US)$)
• $イケナ・オンコロジー(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $ブリッジバイオ・ファーマ(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $クリスタル・バイオテック(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
コラムToday's pre-market stock movers: CRM, WB, LI, NIO and more
• $ヴィクトリアズ・シークレット(VSCO.US)$ +10.4% (In reaction to earnings)
• $セールスフォース(CRM.US)$ +9.0% (In reaction to earnings)
• $ナビゲーター・ホールディングス(NVGS.US)$ +4.9% (names Mads Peter Zacho as CEO)
• $ウェイボー(WB.US)$ +4.7% (In reaction to earnings)
• $CAE(CAE.US)$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US)$ +4% (authorized $200 mln share repurchase program)
• $アクサム・セラピューティクス(AXSM.US)$ +3.1% (Late-Breaking Presentations of P...
コラムTop upgrades and downgrades on 6/1
• $ブループリント・メディスン(BPMC.US)$ : Jefferies Upgrades to Buy from Hold - PT $78 (from $88)
• $CatchMark Timber Trust Inc(CTT.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $ダナハー(DHR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $310 (from $299)
• $エナンタ・ファーマシューティカルズ(ENTA.US)$ : Evercore ISI Upgrades to In Line from Underperform - PT $39 (from $35)
• $フォメント・エコノミコ・メヒカノ(FMX.US)$ : Bradesco BBI Upgrades to Outperform f...
コラムToday's pre-market stock movers: GOOS, TSLA, KSS, UAA and more
• $ロケット・ファーマシューティカルズ(RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $カナダ・グース・ホールディングス(GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $シガテクノロジーズ(SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
まだコメントはありません